3Blondeau JM.A review of the comparative in vitro activities of 12antimicrobial angents,with a focus on five new "respiratory quinolones". J Antimicrob Chemother, 1999,43(SupplB): 1.
1[1]Woodcock J M, Andrews J M, Boswell F J. et al. In vitro activity of BAY 12-8039, a new fluoroquinolone [J]. Antimicrob AgentsChemother , 1997;41:1101
2[2]Hoogkamp-Korstanje J A, Roelofs-Winemse J. Comparative invitro activity of moxitloxacin against Gram-positive clinical isolates[J]. J Antimicrob Chemother, 2000; 45 (1): 31
3[3]Sunderland J, Tobin C M, Hedges A J, et al. Antimicrobial activity of fluoroquinolone photodegradation products determinated byparallel-line bioassay and high performance liquid chromatography[J]. JAntimicrob Chemother, 2001; 47 (3): 271
4[4]Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administation in man [J]. JAntimicrob Chemother, 1999; 43 (Supple B): 83
5[5]Stass H, Dalhoff A. Determination of BAY12-8039, a new 8methoxyquinolone, in human body fluids by high-performance liqnid chromatography with fluorescence detection using on-columnfocusing [J]. J Chromatogr Biomed Appl, 1997; 702 ( 1 ～ 2):163
6[6]Moller J G, Stass H, Heinig R, et al. Capillary electrophoresiswith laser-induced fluorescence: a routine method to determinemoxifloxacin in human body fluids in very small sample volumes[J]. J Chromatog, 1998; 716:325
7[1]Bull P,Make B.Acute exacerbations of chronic bronchitis-an international comparison.Chest,1998,113(3):1998～2048
8[2]Sullivan JT,Woodruff M,Lettien J,et al.Pharmacokinetics(PK)and tolerability of the new mothoxyquinolone BAY 12-8039:10 days' treatment at 400mg.8th ECCMID,1997.359
9[3]Heimer-Bau M,Beyer G,Stass H,et al.Pharmacokinetics(PK)and influence of moxifloxacin(MOX)on bacterial intestinal flora in young male subjects.38th ICCAAC,1998.16
10[4]Stass HH,Kubitza D.Study to evaluate the interaction between moxifloxacin(M)and iron supplements(FE)[abstract T154].Anti-infect Drug Chemother,1998,16(1):74
